CSTL250117C50000
- 0.00
- 0.000.00%
Castle Biosciences Newsroom
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
Analysts' Top Healthcare Picks: Lifecore Biomedical (LFCR), Castle Biosciences (CSTL)
Express News | Castle Biosciences Inc: Expects to Launch Pipeline Test by End of 2025
Castle Biosciences Highlights Progress for Its Pipeline Atopic Dermatitis Gene Expression Profile Test
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $42
Canaccord Genuity Sticks to Its Buy Rating for Castle Biosciences (CSTL)
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's Is How to Trade
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx-Melanoma Test, Contributing to Personalized Management of Patients With Melanoma
Here's Why Agios Stock Plummeted More Than 20% on Monday
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
JANX Stock Hits Record High on Prostate Cancer Study Data
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
Corcept Shares Rise More Than 60% in Three Months: Here's Why
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Castle Biosciences, Inc.'s (NASDAQ:CSTL) Business Is Trailing The Industry But Its Shares Aren't